BioGend Therapeutics Statistics
Total Valuation
BioGend Therapeutics has a market cap or net worth of TWD 4.55 billion. The enterprise value is 3.91 billion.
Market Cap | 4.55B |
Enterprise Value | 3.91B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
Earnings Date | Nov 8, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
BioGend Therapeutics has 124.26 million shares outstanding. The number of shares has increased by 11.65% in one year.
Shares Outstanding | 124.26M |
Shares Change (YoY) | +11.65% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.49% |
Owned by Institutions (%) | 2.56% |
Float | 81.98M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 33.76 |
PB Ratio | 5.02 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -32.31 |
EV / Sales | 29.27 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -29.21 |
Financial Position
The company has a current ratio of 30.20, with a Debt / Equity ratio of 1.24.
Current Ratio | 30.20 |
Quick Ratio | 29.45 |
Debt / Equity | 1.24 |
Debt / EBITDA | n/a |
Debt / FCF | -0.08 |
Interest Coverage | -630.84 |
Financial Efficiency
Return on equity (ROE) is -14.08% and return on invested capital (ROIC) is -9.68%.
Return on Equity (ROE) | -14.08% |
Return on Assets (ROA) | -9.13% |
Return on Capital (ROIC) | -9.68% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.13 |
Inventory Turnover | 1.56 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.27% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +4.27% |
50-Day Moving Average | 36.41 |
200-Day Moving Average | 37.46 |
Relative Strength Index (RSI) | 49.60 |
Average Volume (20 Days) | 221,465 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioGend Therapeutics had revenue of TWD 133.45 million and -120.92 million in losses. Loss per share was -0.98.
Revenue | 133.45M |
Gross Profit | 108.02M |
Operating Income | -153.29M |
Pretax Income | -145.88M |
Net Income | -120.92M |
EBITDA | -102.96M |
EBIT | -153.29M |
Loss Per Share | -0.98 |
Balance Sheet
The company has 655.68 million in cash and 11.23 million in debt, giving a net cash position of 644.44 million or 5.19 per share.
Cash & Cash Equivalents | 655.68M |
Total Debt | 11.23M |
Net Cash | 644.44M |
Net Cash Per Share | 5.19 |
Equity (Book Value) | 908.81M |
Book Value Per Share | 7.29 |
Working Capital | 717.54M |
Cash Flow
In the last 12 months, operating cash flow was -125.27 million and capital expenditures -8.45 million, giving a free cash flow of -133.72 million.
Operating Cash Flow | -125.27M |
Capital Expenditures | -8.45M |
Free Cash Flow | -133.72M |
FCF Per Share | -1.08 |
Margins
Gross margin is 80.95%, with operating and profit margins of -114.87% and -90.61%.
Gross Margin | 80.95% |
Operating Margin | -114.87% |
Pretax Margin | -109.32% |
Profit Margin | -90.61% |
EBITDA Margin | -77.15% |
EBIT Margin | -114.87% |
FCF Margin | -100.21% |
Dividends & Yields
BioGend Therapeutics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -11.65% |
Shareholder Yield | -11.65% |
Earnings Yield | -2.68% |
FCF Yield | -2.94% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |